ACTION-01 (Phase 1b/III)

Investigator physician: Dr Caroline BOURSIER

Phase 1b/3 randomized, controlled, open-label trial comparing RYZ101 with standard treatment in patients with inoperable, advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET) expressing somatostatin receptors (SSTR+) that progressed after prior treatment with a ¹⁷⁷Lu-labeled somatostatin analogue (¹⁷⁷Lu-SSA)

Gastroenteropancreatic neuroendocrine tumors (GEP-NET)

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Treatment: RYZ101 (²²⁵Ac-DOTATATE)
Study status: Recruiting
Clinical Trial number: NCT05595460
Funding: